Novartis signs agreement to acquire Anthos for $925m upfront
Pharmaceutical Technology
FEBRUARY 11, 2025
Novartis has agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage biopharmaceutical company, for an upfront payment of $925m.
Tue.Feb 11, 2025
256 
Radical Study Proposes a Single Cause to Explain Alzheimer’s Disease
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 11, 2025
(koto_feja/E+/Getty Images) A new model of Alzheimer’s disease has been proposed, which could speed up efforts to understand and cure the complex condition while bringing all manifestations of the condition under one unifying theory.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Obesity market to reach $173.5 billion by 2031
Pharmaceutical Technology
FEBRUARY 11, 2025
Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease space.
Novartis pays $925M to reel in a startup it helped launch
Bio Pharma Dive
FEBRUARY 11, 2025
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed to the Blackstone-backed startup six years ago.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
WHO and St Jude start distributing paediatric cancer medicines amid US aid cuts
Pharmaceutical Technology
FEBRUARY 11, 2025
The World Health Organization and St Jude Children's Research Hospital have kicked off a programme to distribute cancer medicines to LMICs.
India needs to develop strategies to mitigate the impact of USAID funding freeze
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 11, 2025
Indian pharmaceutical industry plays a crucial role in the global drug supply chain, particularly in the US. Yet India needs to develop strategies to mitigate the impact of USAID funding freeze for Indian pharma companies.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Project Management Workshop Hones Skills: Core Competencies are Useful for All Roles
ACRP blog
FEBRUARY 11, 2025
People who are entering the clinical research profession can come from many other fields and with very diverse backgrounds. No matter their role, everyone acknowledges project management as an essential and invaluable skill set. Project management requires leadership, communication, and management skills that can be applied in any role across clinical research.
Grace Therapeutics secures $15m for GTx-104 pre-commercial development
Pharmaceutical Technology
FEBRUARY 11, 2025
Grace has announced the initial closing of a financing round, securing almost $15m, for funding pre-commercial development of GTx-104.
Keeping Up with the Clinical Research Compliance Landscape
ACRP blog
FEBRUARY 11, 2025
This is a sponsored message. If theres one thing clinical researchers can count on when it comes to regulations and guidance from governing bodies, its change. In the closing three months of 2024 alone, new guidance documents were drafted or finalized on a number of topics, including: Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations Requests for Reconsideration at the Division Level Under the Generic Drug User Fee Amendments Postoperative Nausea and Vo
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Pharmaceutical Technology
FEBRUARY 11, 2025
Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA-based asset.
Libtayo available in Scotland for cervical cancer patients
Pharma Times
FEBRUARY 11, 2025
New immunotherapy offers hope for recurrent cervical cancer
Bio-Thera signs US deal with Intas for golimumab biosimilar
Pharmaceutical Technology
FEBRUARY 11, 2025
Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in the US.
Velocity Nominated for Two 2025 Vaccine Industry Excellence (ViE) Awards
Velocity Clinical Research
FEBRUARY 11, 2025
Velocity is a nominee for two 2025 Vaccine Industry Excellence (ViE) Awards! After winning the Best Clinical Trial Company ViE Award in 2024, we would be honored to receive your vote and once again share this recognition with you as we work to improve vaccine trials worldwide. Vote now: [link] We look forward to seeing you at the World Vaccine Congress in April.
Be realistic, responsive and transparent: how to engage underperforming sites
Pharmaceutical Technology
FEBRUARY 11, 2025
Sponsors need to try and solve the issue of inadequate enrolment by having better site relationships.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Novartis builds in cardiovascular with $3.1bn Anthos buy
pharmaphorum
FEBRUARY 11, 2025
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Lynparza approved in Scotland for BRCA-mutated breast cancer patients
Pharma Times
FEBRUARY 11, 2025
Treatment expands options for HER2-negative metastatic breast cancer
Ten years on, Roche jettisons InterMune and Esbriet
pharmaphorum
FEBRUARY 11, 2025
It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet.
3PLs: From Resilience to Sustainability
Pharmaceutical Commerce
FEBRUARY 11, 2025
Leaders with top third-party logistics providers discuss the evolving landscape for the sector in 2025and the new strides made in their quest to help transform the pharma supply chain.
Looking beyond the scale: Why measures of physical activity should be incorporated into obesity trials to support long-term sustainable weight loss
pharmaphorum
FEBRUARY 11, 2025
Looking beyond the scale: Why measures of physical activity should be incorporated into obesity trials to support long-term sustainable weight loss Mike.
Pharma Pulse 2/11/25: Revolutionizing Patient Adherence, What Does ‘Cure’ Really Mean? & more
Pharmaceutical Commerce
FEBRUARY 11, 2025
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
Ten years on, Roche jettisons InterMune and Esbriet in US
pharmaphorum
FEBRUARY 11, 2025
It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet.
Keeping a Finger on the Regulatory Pulse
Pharmaceutical Commerce
FEBRUARY 11, 2025
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, discusses some of the other specific regulatory updates that drug developers be closely monitoring in the current landscape.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Merck confirms its interest in buying SpringWorks
pharmaphorum
FEBRUARY 11, 2025
Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming
Conference Connect: Navigating the Future of Pharma Trade
Pharmaceutical Commerce
FEBRUARY 11, 2025
Trade & Channel Strategies conference explores the frontline issues related to strategy, distribution, and reimbursementwhile digging into creative solutions to solve them.
Boehringer drug scores in another pulmonary fibrosis trial
pharmaphorum
FEBRUARY 11, 2025
Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
Bio Pharma Dive
FEBRUARY 11, 2025
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
5 takeaways from Super Bowl LIX: What health and pharma can learn from it
pharmaphorum
FEBRUARY 11, 2025
Discover 5 key takeaways from Super Bowl LIX that can be applied to the healthcare and pharmaceutical industries, focusing on learnings related to celebrities, healthcare trends, and diversity, equity, and inclusion (DEI) initiatives.
Using Drug Patents to Block Competitors: The Tactics and Consequences
Drug Patent Watch
FEBRUARY 11, 2025
The Dark Side of Innovation: How Companies Use Drug Patents to Block Competitors As we celebrate the breakthroughs in medical research and the development of life-saving treatments, it's essential to acknowledge the complex landscape of pharmaceutical innovation. Behind the scenes, companies are employing clever tactics to protect their intellectual property and block competitors from entering the market.
Webinar Recap: Enabling Site Success – Key Insights to Reducing Burden and Increasing Access
pharmaphorum
FEBRUARY 11, 2025
Discover key insights on reducing burden and increasing access to enable site success in this webinar recap from Syneos. Learn valuable tips and strategies for optimizing your study sites.
International Day of Women and Girls in Science 2025: Breaking Barriers to Shape the Future
XTalks
FEBRUARY 11, 2025
February 11 is the annual International Day of Women and Girls in Science 2025, a global observance dedicated to recognizing the contributions of women in STEM (science, technology, engineering and mathematics) and advocating for gender equality in scientific fields. This year marks 10 years since the day was established by the United Nations General Assembly (UNGA) in 2015 by the passing of Resolution A/RES/70/212.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content